- Home
- BMRN
as of 11-28-2025 12:37pm EST
$55.79
+$0.26
+0.48%
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Chart Type:
Time Range:
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 10.5B | IPO Year: | 1999 |
| Target Price: | $90.00 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.68 | EPS Growth: | 59.53 |
| 52 Week Low/High: | $50.76 - $73.51 | Next Earning Date: | 10-27-2025 |
| Revenue: | $3,094,001,000 | Revenue Growth: | 12.39% |
| Revenue Growth (this year): | 13.32% | Revenue Growth (next year): | 7.51% |
AI-Powered BMRN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.51%
75.51%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest BioMarin Pharmaceutical Inc. News
BMRN Breaking Stock News: Dive into BMRN Ticker-Specific Updates for Smart Investing
Compare BMRN vs Leading Stocks
See how BMRN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BMRN BioMarin Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.